Roche's 1H pharma sales rose 6% at CER but fell 1% in CHF, dragging group revenue 1.9% lower. Diagnostics dropped 5%. Alpha Score 49.
Alpha Score of 51 reflects moderate overall profile with moderate momentum, moderate value. Based on 2 of 4 signals – score is capped at 75 until remaining data ingests.
Roche Holding posted first-half non-GAAP earnings of CHF 10.85 a share on revenue of CHF 30.36 billion, a 1.9% decline from a year earlier. The Pharmaceuticals Division brought in CHF 23.6 billion, up 6% at constant exchange rates but down 1% in Swiss francs. That divergence is the headline: currency headwinds erased the pharma unit's organic growth, leaving group revenue lower year on year.
The diagnostics division, Roche's other main leg, did not fare as well. Its sales fell 5% in CHF terms, the company said, without specifying the CER figure. The split matters because diagnostics had been a steady contributor during the pandemic years, and its current weakness adds to the pressure on the top line.
Roche's Alpha Score sits at 49 out of 100, a Mixed label. That middle-of-the-road reading reflects a business with solid pharma assets but limited near-term catalysts and persistent currency drag. The stock page for RHHBY shows the score alongside the sector's healthcare benchmark.
No guidance revision accompanied the release. Roche said it would provide a full-year outlook with its third-quarter results. For now, the market gets a first half that shows growth in pharma volumes but no help from the franc or from diagnostics.
Drafted by a large language model from the source reporting linked above, then screened by automated publishing checks. It is not read by a journalist before publication. Some articles cite our Alpha Score. Verify prices and figures against the original source. Educational coverage, not personalized advice.